Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study

D J Wallace, K Hobbs, M E B Clowse, M Petri, V Strand, M Pike, J T Merrill, P Leszczynski, C M Neuwelt, S Jeka, F Houssiau, M Keiserman, J Ordi-Ros, S Bongardt, B Kilgallen, C Galateanu, K Kalunian, R Furie, C Gordon

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)
174 Downloads (Pure)

Abstract

OBJECTIVE: The primary objective was to assess the long-term safety of repeated courses of epratuzumab therapy in patients with moderate-to-severe systemic lupus erythematosus. Secondary objectives were to assess long-term efficacy and health-related quality of life (HRQoL).

METHODS: Eligible patients from the 12-week, phase IIb, randomized, placebo-controlled EMBLEM™ study (NCT00624351) enrolled into the open-label extension (OLE) study, SL0008 (NCT00660881). In SL0008, patients received 1200 mg epratuzumab infusions at Weeks 0 and 2 of repeating 12-week cycles, plus standard of care. Safety measures included treatment-emergent adverse events (TEAEs) and serious TEAEs. Efficacy measures included combined treatment response, BILAG score, SLEDAI score, physician's and patient's global assessment of disease activity. Total daily corticosteroid dose and HRQoL (SF-36) were also assessed.

RESULTS: 113 of the 203 patients who entered SL0008 (55.7%) continued epratuzumab therapy until study closure (total cumulative exposure: 381.3 patient-years; median exposure: 845 days; maximum exposure: 1185 days/approximately 3.2 years). TEAEs were reported in 192 patients (94.6%), most commonly infections and infestations (68.0%; 138 patients). Serious TEAEs were reported in 51 patients (25.1%); 14 (6.9%) serious infections. In patients treated for 108 weeks (n=116), median corticosteroid dose was reduced from 10.0 mg/day at OLE screening to 5.0 mg/day at Week 108. Improvements in efficacy and HRQoL measures in EMBLEM™ were maintained in the OLE, while placebo patients exhibited similar improvements in disease activity upon switch to epratuzumab.

CONCLUSION: Open-label epratuzumab treatment was well-tolerated for up to 3.2 years, and associated with sustained improvements in disease activity and HRQoL, while steroids were reduced. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)534-543
Number of pages10
JournalArthritis Care & Research
Volume68
Issue number4
Early online date28 Aug 2015
DOIs
Publication statusPublished - 1 Apr 2016

Bibliographical note

© 2015, American College of Rheumatology.

Keywords

  • systemic lupus erythematosus
  • epratuzumab
  • biologics

Fingerprint

Dive into the research topics of 'Long-term safety and efficacy of epratuzumab in the treatment of moderate-to-severe systemic lupus erythematosus: results from an open-label extension study'. Together they form a unique fingerprint.

Cite this